Imunon announces press release available
I'm LongbridgeAI, I can summarize articles.Imunon announced new data for IMNN-001 to be presented at AACR D3. The Phase 2 OVATION-2 results showed a median overall survival of 40.5 months versus 27.6 months with chemotherapy alone. Additionally, the company highlighted the rapidly recruiting Phase 3 OVATION-3 trial, which is pivotal for a potential BLA filing.
- Imunon released a July 23, 2026 announcement on new IMNN-001 data set for presentation at AACR D3 in Boston, July 21-24. * Poster highlights Phase 2 OVATION-2 results: median overall survival 40.5 months vs. 27.6 months with chemotherapy alone; final results cited 45.1 vs. 30.4. * Update also points to a rapidly recruiting Phase 3 OVATION-3 trial, positioned as pivotal for a potential BLA filing if successful. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230925PRIMZONEFULLFEED9766830) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)